| 1 |
31744897 | Dual mTORC1/2 Inhibition Sensitizes Testicular Cancer Models to Cisplatin Treatment. | 2020 Feb |
1 |
| 2 |
33597869 | Regulating T Cell Population Alleviates SLE by Inhibiting mTORC1/C2 in MRL/lpr Mice. | 2020 |
2 |
| 3 |
30766792 | Exploration of the chondrosarcoma metabolome; the mTOR pathway as an important pro-survival pathway. | 2019 Apr |
1 |
| 4 |
30981761 | Combined class I histone deacetylase and mTORC1/C2 inhibition suppresses the initiation and recurrence of oral squamous cell carcinomas by repressing SOX2. | 2019 Jul 10 |
1 |
| 5 |
31160383 | Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models. | 2019 Sep |
1 |
| 6 |
25893295 | Inhibition of mTOR complex 2 induces GSK3/FBXW7-dependent degradation of sterol regulatory element-binding protein 1 (SREBP1) and suppresses lipogenesis in cancer cells. | 2016 Feb 4 |
1 |
| 7 |
27574017 | The novel mTORC1/2 dual inhibitor INK128 enhances radiosensitivity of breast cancer cell line MCF-7. | 2016 Sep |
2 |
| 8 |
25519700 | MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue sarcoma. | 2015 Feb |
2 |
| 9 |
26452980 | Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation. | 2015 Dec |
1 |
| 10 |
24562770 | mTORC1/C2 and pan-HDAC inhibitors synergistically impair breast cancer growth by convergent AKT and polysome inhibiting mechanisms. | 2014 Apr |
2 |
| 11 |
25162417 | A critical role for the mTORC2 pathway in lung fibrosis. | 2014 |
1 |
| 12 |
25261369 | Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors. | 2014 Sep 30 |
1 |
| 13 |
23828865 | Targeting mTOR in RET mutant medullary and differentiated thyroid cancer cells. | 2013 Oct |
1 |
| 14 |
23085766 | Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models. | 2012 Dec |
1 |